RBC Capital analyst Gregory Renza maintained a Buy rating on Morphic Holding (NASDAQ:MORF) Inc on Wednesday, setting a price target of $82, which is approximately 44.16% above the present share price of $56.88.
Renza expects Morphic Holding Inc to post earnings per share (EPS) of -$0.63 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Morphic Holding, with an average price target of $92.
The analysts price targets range from a high of $102 to a low of $82.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $3.27 million and a net profit of -$21.3 million. The company's market cap is $2.06 billion.
According to TipRanks.com, RBC Capital analyst Gregory Renza is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.5% and a 29.35% success rate.
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.